SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 300M 600M 900M Q1 '12: 1M Q2 '12: 352K Q3 '12: 432K Q4 '12: 1.5M Q1 '13: 1.4M Q2 '13: 1.6M Q3 '13: 2.8M Q4 '13: 12M Q1 '14: 21M Q2 '14: 50.3M Q3 '14: 71.8M Q4 '14: 92.7M Q1 '15: 112.3M Q2 '15: 118.3M Q3 '15: 135M Q4 '15: 147.5M Q1 '16: 162.9M Q2 '16: 178.9M Q3 '16: 196.3M Q4 '16: 215M Q1 '17: 228.4M Q2 '17: 252.6M Q3 '17: 276.2M Q4 '17: 302.2M Q1 '18: 335.1M Q2 '18: 358.8M Q3 '18: 381.4M Q4 '18: 408.9M Q1 '19: 403.9M Q2 '19: 409.1M Q3 '19: 408.2M Q4 '19: 392.8M Q1 '20: 402.3M Q2 '20: 424.3M Q3 '20: 477.3M Q4 '20: 520.4M Q1 '21: 556.4M Q2 '21: 571M Q3 '21: 564.3M Q4 '21: 579.8M Q1 '22: 601.3M Q2 '22: 630.1M Q3 '22: 659M Q4 '22: 667.2M Q1 '23: 668.5M Q2 '23: 634M Q3 '23: 610.5M Q4 '23: 607.5M Q1 '24: 597.4M Q2 '24: 630.2M Q3 '24: 652M Q4 '24: 661.8M Q1 '25: 668M Q2 '25: 665.1M Q3 '25: 681.5M Q4 '25: 719M Q1 '26: 776.8M Q2 '26: 830.4M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit TTM

0 250M 500M 750M Q4 '17: 287M Q1 '18: 319.5M Q2 '18: 343.4M Q3 '18: 366.1M Q4 '18: 393.5M Q1 '19: 388.2M Q2 '19: 393M Q3 '19: 391.5M Q4 '19: 376.1M Q1 '20: 385.1M Q2 '20: 402.8M Q3 '20: 439.2M Q4 '20: 467.9M Q1 '21: 493.1M Q2 '21: 491.1M Q3 '21: 487.7M Q4 '22: 580M Q1 '23: 575.7M Q2 '23: 540.6M Q3 '23: 523.4M Q4 '23: 523.7M Q1 '24: 520.8M Q2 '24: 556.7M Q3 '24: 580.5M Q4 '24: 583.9M Q1 '25: 590.6M Q2 '25: 588.9M Q3 '25: 603.9M Q4 '25: 644.4M Q1 '26: 694.6M Q2 '26: 731.4M Q2 '18 Q2 '19 Q2 '20 Q2 '21 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q4 '11: -37.8M Q1 '12: -36.4M Q2 '12: -37.3M Q3 '12: -39.7M Q4 '12: -42.2M Q1 '13: -52.2M Q2 '13: -58.4M Q3 '13: -63.3M Q4 '13: -61.9M Q1 '14: -57.4M Q2 '14: -38.2M Q3 '14: -21.8M Q4 '14: -5.3M Q1 '15: 12.2M Q2 '15: 12.3M Q3 '15: 18.1M Q4 '15: 20.8M Q1 '16: 23.2M Q2 '16: 31M Q3 '16: 45.8M Q4 '16: 54.2M Q1 '17: 64.6M Q2 '17: 79M Q3 '17: 81.5M Q4 '17: 99.5M Q1 '18: 114.1M Q2 '18: 123.8M Q3 '18: 138.9M Q4 '18: 144.4M Q1 '19: 138.5M Q2 '19: 145.4M Q3 '19: 147.6M Q4 '19: 148.6M Q1 '20: 152.2M Q2 '20: 155.1M Q3 '20: 171.5M Q4 '20: 173.7M Q1 '21: 157.9M Q2 '21: 146.5M Q3 '21: 122.9M Q4 '21: 86M Q1 '22: 74.8M Q2 '22: 52M Q3 '22: 17.9M Q4 '22: 46.1M Q1 '23: 49.3M Q2 '23: 20.4M Q3 '23: 30.1M Q4 '23: -5.3M Q1 '24: -13.6M Q2 '24: 26.6M Q3 '24: 59.3M Q4 '24: 81.7M Q1 '25: 74.6M Q2 '25: 64.1M Q3 '25: -36.9M Q4 '25: -62.3M Q1 '26: -60.4M Q2 '26: -130.5M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '11: 53.8M Q1 '12: 55.6M Q2 '12: 49.5M Q3 '12: 45.7M Q4 '12: -49.8M Q1 '13: -58.9M Q2 '13: -72.8M Q3 '13: -83.4M Q4 '13: -92.3M Q1 '14: -89.4M Q2 '14: -58.8M Q3 '14: -37.1M Q4 '14: -10.9M Q1 '15: 5.4M Q2 '15: 4.6M Q3 '15: 10.9M Q4 '15: 13.9M Q1 '16: 18M Q2 '16: 25.8M Q3 '16: 83.8M Q4 '16: 91.2M Q1 '17: 96.7M Q2 '17: 103.8M Q3 '17: 57.9M Q4 '17: 57.3M Q1 '18: 73.3M Q2 '18: 86.7M Q3 '18: 98.8M Q4 '18: 111M Q1 '19: 103M Q2 '19: 105M Q3 '19: 105.8M Q4 '19: 113.1M Q1 '20: 116.2M Q2 '20: 118.2M Q3 '20: 129.3M Q4 '20: 127M Q1 '21: 111.1M Q2 '21: 100.2M Q3 '21: 81.8M Q4 '21: 53.4M Q1 '22: 73.3M Q2 '22: 57.5M Q3 '22: 37.7M Q4 '22: 60.7M Q1 '23: 52M Q2 '23: 43.3M Q3 '23: 25.6M Q4 '23: 1.3M Q1 '24: -15.5M Q2 '24: 5.2M Q3 '24: 59.7M Q4 '24: 73.9M Q1 '25: 61.9M Q2 '25: 64.5M Q3 '25: -19.1M Q4 '25: -38.5M Q1 '26: -29M Q2 '26: -109.9M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Cost of Revenue TTM

0 35M 70M 105M Q4 '17: 15.2M Q1 '18: 15.5M Q2 '18: 15.4M Q3 '18: 15.3M Q4 '18: 15.4M Q1 '19: 15.8M Q2 '19: 16.1M Q3 '19: 16.7M Q4 '19: 16.7M Q1 '20: 17.1M Q2 '20: 21.5M Q3 '20: 38M Q4 '20: 52.5M Q1 '21: 63.3M Q2 '21: 79.9M Q3 '21: 76.6M Q4 '21: 75.1M Q1 '22: 78M Q2 '22: 73.5M Q3 '22: 81.3M Q4 '22: 87.2M Q1 '23: 92.7M Q2 '23: 93.4M Q3 '23: 87.1M Q4 '23: 83.8M Q1 '24: 76.6M Q2 '24: 73.5M Q3 '24: 71.4M Q4 '24: 77.9M Q1 '25: 77.4M Q2 '25: 76.3M Q3 '25: 77.7M Q4 '25: 74.6M Q1 '26: 82.2M Q2 '26: 99M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-70M 0 70M 140M 210M Q4 '11: -36.2M Q1 '12: -36.5M Q2 '12: -37.1M Q3 '12: -39.3M Q4 '12: -47.2M Q1 '13: -54.4M Q2 '13: -60.4M Q3 '13: -64.7M Q4 '13: -57.9M Q1 '14: -59.8M Q2 '14: -51M Q3 '14: -40.2M Q4 '14: -24.5M Q1 '15: -4.9M Q2 '15: 16.7M Q3 '15: 20.9M Q4 '15: 34.5M Q1 '16: 30.9M Q2 '16: 33M Q3 '16: 61.8M Q4 '16: 66.8M Q1 '17: 83.3M Q2 '17: 92.5M Q3 '17: 103.2M Q4 '17: 114.6M Q1 '18: 128.4M Q2 '18: 109M Q3 '18: 132.5M Q4 '18: 129M Q1 '19: 134.8M Q2 '19: 157M Q3 '19: 132.2M Q4 '19: 143.1M Q1 '20: 119.1M Q2 '20: 182.3M Q3 '20: 150.3M Q4 '20: 138.4M Q1 '21: 165.7M Q2 '21: 120M Q3 '21: 110.3M Q4 '21: 127.1M Q1 '22: 95.2M Q2 '22: 120.1M Q3 '22: 138M Q4 '22: 116.8M Q1 '23: 161.7M Q2 '23: 71.7M Q3 '23: 93.7M Q4 '23: 111.1M Q1 '24: 100.4M Q2 '24: 154.9M Q3 '24: 172.5M Q4 '24: 172M Q1 '25: 164.1M Q2 '25: 187.1M Q3 '25: 71.9M Q4 '25: 47.3M Q1 '26: 83.3M Q2 '26: 19.9M Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow TTM

-70M 0 70M 140M 210M Q4 '11: -36.9M Q1 '12: -37M Q2 '12: -37.5M Q3 '12: -40.1M Q4 '12: -48M Q1 '13: -55.4M Q2 '13: -62M Q3 '13: -66.3M Q4 '13: -59.6M Q1 '14: -61.4M Q2 '14: -52M Q3 '14: -40.9M Q4 '14: -25.1M Q1 '15: -5.4M Q2 '15: 15.7M Q3 '15: 19.5M Q4 '15: 32.4M Q1 '16: 28.7M Q2 '16: 30.8M Q3 '16: 59.6M Q4 '16: 65.2M Q1 '17: 81.7M Q2 '17: 90.9M Q3 '17: 101.7M Q4 '17: 112.6M Q1 '18: 126.4M Q2 '18: 107.3M Q3 '18: 131M Q4 '18: 128.1M Q1 '19: 134M Q2 '19: 156.4M Q3 '19: 131.4M Q4 '19: 140.4M Q1 '20: 114M Q2 '20: 176.8M Q3 '20: 145M Q4 '20: 134.9M Q1 '21: 163.3M Q2 '21: 118.1M Q4 '22: 116.4M Q1 '23: 161.5M Q2 '23: 71.1M Q3 '23: 93.1M Q4 '24: 171.2M Q1 '25: 163.3M Q2 '25: 185.9M Q3 '25: 70.8M Q4 '25: 46M Q1 '26: 82.2M Q2 '26: 18.8M Q4 '11 Q3 '13 Q2 '15 Q1 '17 Q4 '18 Q3 '20 Q3 '23 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '11: 1.6M Q2 '11: 1.6M Q1 '12: 1.7M Q2 '12: 16.8M Q2 '13: 30.9M Q3 '13: 30.9M Q1 '14: 41.1M Q2 '14: 42.4M Q3 '14: 42.9M Q1 '15: 44.9M Q2 '15: 52.3M Q3 '15: 51.6M Q1 '16: 51.2M Q2 '16: 51.7M Q3 '16: 52M Q1 '17: 52.8M Q2 '17: 53.2M Q3 '17: 53.6M Q1 '18: 53.8M Q2 '18: 54.2M Q3 '18: 54.2M Q1 '19: 54M Q2 '19: 53.9M Q3 '19: 53.8M Q1 '20: 53.6M Q2 '20: 53.6M Q3 '20: 53.8M Q1 '21: 54.2M Q2 '21: 54.7M Q3 '21: 54.3M Q1 '22: 61.4M Q2 '22: 61.4M Q3 '22: 55M Q1 '23: 62.5M Q2 '23: 54.5M Q3 '23: 54.6M Q1 '24: 55.6M Q2 '24: 55.7M Q3 '24: 56M Q1 '25: 55.9M Q2 '25: 56.6M Q3 '25: 56.6M Q1 '26: 57.6M Q2 '26: 58.1M Q2 '11 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 0.00 15.00 30.00 45.00 Q4 '11: 31.38 Q1 '12: 32.81 Q2 '12: 37.37 Q3 '12: 43.46 Q4 '12: -7.72 Q1 '13: -2.27 Q2 '13: -2.55 Q3 '13: -2.78 Q4 '13: -2.92 Q1 '14: -2.70 Q2 '14: -1.73 Q3 '14: -1.01 Q4 '14: -0.27 Q1 '15: 0.13 Q2 '15: 0.09 Q3 '15: 0.23 Q4 '15: 0.28 Q1 '16: 0.34 Q2 '16: 0.48 Q3 '16: 1.58 Q4 '16: 1.70 Q1 '17: 1.81 Q2 '17: 1.95 Q3 '17: 1.06 Q4 '17: 1.06 Q1 '18: 1.36 Q2 '18: 1.61 Q3 '18: 1.84 Q4 '18: 2.06 Q1 '19: 1.91 Q2 '19: 1.95 Q3 '19: 1.97 Q4 '19: 2.11 Q1 '20: 2.17 Q2 '20: 2.21 Q3 '20: 2.41 Q4 '20: 2.36 Q1 '21: 2.07 Q2 '21: 1.85 Q3 '21: 1.51 Q4 '21: 0.98 Q1 '22: 1.30 Q2 '22: 1.01 Q3 '22: 0.64 Q4 '22: 1.02 Q1 '23: 0.88 Q2 '23: 0.72 Q3 '23: 0.40 Q4 '23: 0.02 Q1 '24: -0.27 Q2 '24: 0.11 Q3 '24: 1.09 Q4 '24: 1.32 Q1 '25: 1.11 Q2 '25: 1.15 Q3 '25: -0.34 Q4 '25: -0.68 Q1 '26: -0.51 Q2 '26: -1.92 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.